Eli Lilly (LLY) Lowers Prices for Weight Loss Drug Zepbound
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Source: TipRanks
Eli Lilly Reduces Zepbound Prices: Eli Lilly is lowering the cost of its weight loss medication Zepbound, offering higher doses in single-dose vials at about half the usual price to increase accessibility for uninsured patients.
Stock Performance and Analyst Ratings: The company's stock has risen 19% over the past year, with a consensus Strong Buy rating from analysts, indicating positive expectations for future performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
